Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047734 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,320
- Enrollment target
NCT02047734 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,320 participants.
The verdict
NCT02047734, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,320 participants
- Enrollment target
Study Summary
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
Interventions
- DRUG Ozanimod
- DRUG Interferon beta-1a
- DRUG Ozanimod placebo
- DRUG Interferon beta-1a placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,320 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2017-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047734
The ClinicalTrials.gov registry entry for NCT02047734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ozanimod is the first listed.
NCT02047734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047734 about?
NCT02047734 is a clinical study titled "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis". This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical rel...
What is the current status of trial NCT02047734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,320 participants. The study started on 2013-12-03. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT02047734?
The interventions under investigation include: Ozanimod (DRUG), Interferon beta-1a (DRUG), Ozanimod placebo (DRUG), Interferon beta-1a placebo (DRUG).
Who is sponsoring clinical trial NCT02047734?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.